Table 1 Baseline Characteristics of patients stratified by mortality and renal failurea
Baseline Characteristics | Entire Cohort (n = 3687) | Survivors (n = 3588) | Non-Survivors (n = 99) | P Value | No Renal Failure (n = 3582) | Renal Failure (n = 105) | P Value |
|---|---|---|---|---|---|---|---|
Age, yearsb | 68 (60, 76) | 68 (60, 76) | 72 (62, 78) | 0.002* | 68 (60, 76) | 73 (59, 81) | 0.03 |
Male genderc | 2565 (69.57) | 2505 (69.82) | 60 (60.61) | 0.049* | 2496 (69.68) | 69 (65.71) | 0.38 |
Baseline Comorbidities | |||||||
 Hypertension | 2900 (78.65) | 2817 (78.51) | 83 (83.84) | 0.20 | 2808 (78.39) | 92 (87.62) | 0.02* |
 Congestive Heart Failure | 1024 (27.77) | 969 (27.01) | 55 (55.56) | < 0.0001* | 967 (27.00) | 57 (54.29) | < 0.0001* |
 Cerebrovascular Disease | 550 (14.92) | 521 (14.52) | 29 (29.29) | < 0.0001* | 521 (14.54) | 29 (27.62) | 0.0002* |
 Dyslipidaemia | 2702 (73.28) | 2635 (73.44) | 67 (67.68) | 0.20 | 2631 (73.45) | 71 (67.62) | 0.18 |
 Previous Myocardial Infarction | 1120 (30.38) | 1073 (29.91) | 47 (47.47) | 0.0002* | 1082 (30.21) | 38 (36.19) | 0.19 |
 Diabetes | 1154 (31.30) | 1116 (31.10) | 38 (38.38) | 0.12 | 1116 (31.16) | 38 (36.19) | 0.27 |
 Chronic Lung Disease | 499 (13.53) | 473 (13.18) | 26 (26.26) | 0.0002* | 476 (13.29) | 23 (21.90) | 0.01* |
 Dialysis | 84 (6.27) | 80 (2.23) | 4 (4.04) | 0.29 | 0 | 84 | 0.18 |
LVEF†| 52.5 (50.0, 60.0) | 52.5 (50.0, 60.0) | 52.5 (50.0, 56.25) | 0.18 | 52.5 (50.0, 60.0) | 52.5 (50.0, 57.5) | 0.17 |
Preoperative Medicationsc | |||||||
 Aspirin | 2984 (80.93) | 2904 (80.94) | 80 (80.81) | 0.97 | 2900 (80.96) | 84 (80.00) | 0.81 |
 β-Blockers | 2714 (73.61) | 2643 (73.66) | 71 (71.72) | 0.66 | 2640 (73.7) | 74 (70.48) | 0.46 |
 ACE-I or ARBS | 1621 (43.97) | 1579 (44.01) | 42 (42.42) | 0.75 | 1575 (43.97) | 46 (43.81) | 0.97 |
 Lipid Lowering | 2782 (75.45) | 2713 (75.61) | 69 (69.70) | 0.18 | 2706 (75.54) | 76 (72.38) | 0.46 |
 Steroids | 146 (3.96) | 135 (3.76) | 11 (11.11) | 0.002* | 139 (3.88) | 7 (6.67) | 0.19 |
Intraoperative vasopressor-inotropes. Mgb | 0.63 (0.30, 1.15) | 0.63 (0.30, 1.12) | 0.99 (0.29, 3.03) | 0.01 | 0.63 (0.31, 1.13) | 0.69 (0.13, 2.75) | 0.36 |
Surgical Characteristics | |||||||
 Surgery Type | |||||||
  CABG | 1751 (47.49) | 1722 (47.99) | 29 (29.29) | < 0.0001* | 1725 (48.16) | 26 (24.76) | < 0.0001* |
  CABG + Valve | 725 (19.66) | 687 (19.15) | 38 (38.38) | 689 (19.24) | 36 (34.29) | ||
  Valved | 1097 (29.75) | 1076 (29.99) | 21 (21.21) | 1059 (29.56) | 38 (36.19) | ||
  Other | 114 (3.09) | 103 (2.87) | 11 (11.11) | 109 (3.04) | 5 (4.76) | ||
STS Risk Score for Morbidity and Mortalityb | 0.01 (0.01, 0.03) n = 2732 | 0.01 (0.01, 0.03) n = 2686 | 0.06 (0.02, 0.11) n = 46 | < 0.0001* | 0.01 (0.01, 0.03) n = 2671 | 0.05 (0.02, 0.11) n = 61 | < 0.0001* |
STS Predicted Risk Score for Renal Failureb | 0.03 (0.01, 0.06) n = 2670 | 0.03 (0.01, 0.06) n = 2625 | 0.09 (0.04, 0.17) n = 45 | < 0.0001* | 0.03 (0.01, 0.06) n = 2609 | 0.11 (0.04, 0.21) n = 61 | < 0.0001* |
Bypass Period Time, minutesb | |||||||
 Pre-Bypass | 126.0 (104.3, 148.8) | 125.8 (104.3, 148.5) | 141.5 (108.3, 170.8) | 0.004* | 125.8 (104.3, 148.5) | 134.8 (108.3, 161.8) | 0.02* |
 Bypass | 79.3 (63.8, 100.0) | 79.0 (63.7, 99.0) | 105.8 (75.2, 141.3) | < 0.0001* | 79.0 (63.5, 99.0) | 102.5 (75.8, 133.7) | < 0.0001* |
 Post-Bypass | 76.5 (65.8, 90.8) | 76.3 (65.8, 89.8) | 95.5 (79.5, 135.5) | < 0.0001* | 76.3 (65.8, 90.0) | 92.3 (74.8, 120.8) | < 0.0001* |
Cross Clamp Time, minutesb | 71.0 (56.0, 91.0) | 71.0 (56.0, 91.0) | 93.0 (65.0, 129.0) | < 0.0001* | 71.0 (56.0, 91.0) | 94.5 (67.5, 120.0) | < 0.0001* |